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Abstract: Acute exacerbations are a leading cause of worsening COPD in terms of lung  function 
decline, quality of life, and survival. They also have a relevant economic burden on the health 
care system. Determining the risk factors for acute exacerbation and early relapse could be a 
crucial element for a better management of COPD patients. This review analyzes the current 
knowledge and underlines the main risk factors for recurrent acute exacerbations. Comprehensive 
evaluation of COPD patients during stable phase and exacerbation could contribute to prevent 
treatment failure and relapses.
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Introduction
Acute exacerbation of COPD (AECOPD) represents a key moment in the progres-
sion of COPD. The association between AECOPD and decline in health status and 
lung function is well recognized.1,2 These events absorb around 50% of direct cost 
for COPD.3 
The true incidence of AECOPD is quite difficult to assess because about 50% 
of exacerbations are not reported by patients.4 However, it is known that AECOPD 
causes 2.4% of acute hospitalizations in England. The median length of hospital stay 
is around 7 days with an overall mortality rate of 11.6%, which increases up to 37% 
in patients who required readmission.5 
Mortality rate during the 3 months following hospitalization is approximately 
15%. These data are confirmed by the retrospective subanalysis of the UPLIFT study 
published in 2012.6,7 
AECOPD-related costs are estimated around $4069/year per patient, but 
costs increase with exacerbation frequency and severity and with the presence of 
comorbidities.8 Hospitalization represents more than 70% of all COPD-related health 
care costs.9,10 In addition, relapses have even higher costs, estimated to be 18% greater 
than for patients who do not require new hospitalization.11 
Some patients experience frequent episodes and have an increased risk of recurrence 
or relapse following the initial episode.12 Patients with a high exacerbation rate have 
an increased annual decline of lung function,13 poorer health outcomes and increased 
hospital admissions.14–16 
In the USA, in a cohort of Medicare fee-for-service patients, the rate of AECOPD 
patients with early readmittance was estimated to be approximately 20%.17,18 Similar 
to other complex clinical conditions that need strict monitoring post discharge (such 
as congestive heart failure),17,18 there is a strong interest in identifying which clinical 
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factors increase the risk of relapse in COPD patients, given 
the high impact of readmissions.19,20 
Reducing the treatment failure and relapse of AECOPD 
could contribute to reduce the burden of disease and improve 
the management of COPD patients.
This narrative review of the literature analyzes the defini-
tion and factors associated with treatment failure and relapses 
of AECOPD to understand how to perform an early diagnosis 
and prompt intervention to reduce the risk of failure and 
relapse of AECOPD.
Definition of failure and early 
relapse of AECOPD
Main goals of the treatment are cure, defined as the com-
plete resolution of signs and symptoms associated with the 
exacerbation and improvement and defined as a resolution or 
reduction in the symptoms and signs without new symptoms 
and signs associated with the exacerbation.21 
Clinical success is considered when either cure or 
improvement is observed at the end of the treatment.22 
Failure of AECOPD treatment is differently defined on 
the basis of the severity and clinical setting where the patients 
need to be managed.
In outpatients, with mild-to-moderate exacerbation, 
failure is generally defined as an incomplete resolution, 
persistence or worsening of symptoms that require a 
new course of antibiotics and/or oral corticosteroids or 
hospitalization.22,23 
In severe COPD patients who need hospitalization or 
access to emergency room, failure is defined as death due to 
AECOPD or its complication, initiation of mechanical ventila-
tion after the second hospital day, intubation with mechanical 
ventilation, intensification of pharmacologic therapy or hospi-
tal readmission for COPD within 30 days of discharge.24–26 
Even after a clinical success in the treatment of acute 
exacerbation, patients could experience a recurrence of 
AECOPD. Although there is no uniform characterization 
regarding length of time, a new hospitalization between day 
7 and day 30 following discharge is defined as an “early 
readmission.”27 Generally, the need for readmission may be 
related to a further COPD exacerbation or to other causes 
(ie, pneumonia and heart failure).22 
From a clinical point of view, the early readmission to 
hospital should be considered as a marker of a more severe 
disease with a worse prognosis.28 A readmission for a new 
event of AECOPD in a period of 30 days of discharge is 
proved to have an impact on mortality in a short- and long-
term follow-up;29 in the readmitted patients, in fact, the 
estimated absolute risk of death was 4%, 17%, 19% and 24% 
at 30 days, 6 months, 1 year and 3 years, respectively.29
Risk factors for relapse and failure 
of AECOPD
A significant number of patients (12%–32% of patients 
depending on the severity of underlying disease, comorbidities 
and time from previous exacerbation) treated for AECOPD 
tend to relapse in the days and weeks after treatment.30 
Same factors are associated with the risk of failure 
and relapse,31 and clinicians should identify them in every 
AECOPD patient to implement effective interventions.
Severity of underlying COPD
Several studies have identified clinical and conventional 
laboratory parameters associated with higher rates of readmis-
sion following an AECOPD. These variables include age,32 
sex,33–35 physical capacity,32 levels of partial arterial oxygen 
pressure (PaO
2
)35,36 and partial arterial carbon dioxide pres-
sure (PaCO
2
),37,38 global and respiratory muscle weakness,39,40 
socioeconomic status, health-related quality of life and 
anxiety or depression,35,40–44 cured meat consumption45 and 
adherence to inhaled therapy and follow-up.46 The severity of 
underlying COPD mostly influences outcomes.47 In particu-
lar, a higher risk of relapse was seen in patients with markers 
of disease severity such as low body mass index (BMI), use of 
systemic corticosteroids and the need of LAMA and LABA 
treatments for severe obstruction and hyperinflation.46
In addition, the frequency of exacerbations is related to 
a higher readmission rate within 90 days.48
Clinical factors related to early readmission include 
lung function and dyspnea perception.22,43,49 Two studies, 
one prospective36 and one retrospective,43 both performed 
with a period of 1-year observation and performed on 34036 
and 18643 AECOPD patients, respectively, found airflow 
obstruction severity, measured by forced expiratory volume 
in 1 second (FEV
1
) to be an important predictor factor for 
AECOPD readmission during stable phase. In general, FEV
1
 
values below 50% of predicted are associated with a higher 
risk of COPD readmission. An English prospective trial,49 
recruiting more than 900 severe COPD patients and aimed 
at evaluating the role of dyspnea in AECOPD, confirmed 
a readmission rate of 19% at 28 days and 33% at 90 days 
following discharge.
Severity of AeCOPD
The European COPD Audit in 2016 found respiratory 
acidosis and the subsequent need for ventilator support as 
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predictors of failure and poor outcome, both during hospital 
stay and 3 months after discharge.49 Thus, arterial blood gas 
analysis must be performed in every AECOPD patient, as 
a prompt noninvasive ventilation trial could be effective on 
patient outcomes.
At presentation, respiratory rate and self-reported activity 
limitations are significantly associated with later relapse.33 
Comorbidities
Clinical factors related to lung involvement are not the only 
elements involved in the risk of an early relapse after an 
AECOPD. Almagro et al50 in a longitudinal, multicenter 
Spanish study evaluated the influence of chronic comorbidi-
ties as risk factors for readmission and short-term prognosis 
of AECOPD patients. The authors enrolled more than 
600 patients with an acute exacerbation and found a 20% rate 
of readmission in the 3-month period after discharge. New 
findings of this study are related to the ability of high values 
of the Charlson index, coupled with the number of comorbidi-
ties, to act as predictive factors for a new AECOPD readmis-
sion. In particular, the stratification of the Charlson index in 
two or more points (2 or .2 comorbidities other than COPD) 
increased the risk of readmission. Moreover, the Charlson 
index was significantly higher in patients who required 
a rehospitalization also for causes other than AECOPD 
(particularly heart failure and infections). However, data 
of Almagro et al50 were not confirmed when the role of two 
common comorbidities associated with COPD such as dia-
betes and hypertension was evaluated.37 McGhan et al51 in a 
large cohort of Veterans Affairs (VA) patients (.50,000), 
quantified a 25% readmission rate at 1 year, and a 44% rate 
at 5 years. The authors identified an increasing risk for some 
comorbidities (asthma and pulmonary hypertension), but a 
reduced risk of readmission for other comorbidities such 
as diabetes and arterial hypertension (protective effect). 
Although diabetes and hypertension were found to exert a 
weak protective influence on COPD severity (as measured by 
health care utilization),52 the study by McGhan et al51 used a 
retrospective administrative database with non-confirmed 
definitions of chronic conditions associated with COPD, and 
this aspect may play an important role in this discrepancy.52 
In addition, a recent Spanish prospective study, defining 
predictors of early readmission for AECOPD (30 days after 
discharge), found that patients with a greater prevalence of 
diabetes have a high risk of readmission. Moreover, diabetes 
was one of three only significant variables predicting an early 
readmission to hospital.53 In terms of single and specific 
comorbidities related to relapse, the association of COPD 
with the presence of cancer,27,43,54 heart failure,36,37 coronary 
disease,36 chronic cor pulmonale, moderate or severe liver 
disease,52 osteoporosis,37 anxiety37 or depression,37 unilateral 
pulmonary infiltrates,26 malnutrition36 and hyperproteinemia41 
exerts a negative role in promoting readmission to hospital. 
Surprisingly, the presence of obesity36 in association with 
COPD conversely shows a protective role.
The presence of bronchiectasis as comorbidity of COPD is 
considered a considerable risk factor for COPD exacerbations 
and for worse long-term outcomes (ie, mortality and quality of 
life).55,56 Different risk factors have been identified to predict 
the risk of bronchiectasis in COPD: male sex, high serum Ig, 
previous tuberculosis, severe airflow obstruction, isolation of a 
pathogen microorganism from sputum and at least one hospital 
admission for exacerbations in the previous year.57,58
Biomarkers
As the underlying biology in COPD is complex and as yet 
not completely understood, biomarkers could be useful in 
the study of different COPD phenotypes and in differenti-
ating patients with frequent exacerbations or at risk for early 
relapse. The ECLIPSE study revealed some biomarkers, 
including C-reactive protein (CRP), fibrinogen, serum 
interleukin 8 (IL-8) surfactant protein D (SP-D), club cell 
protein-16 (CC16) and club cell protein-18 (CC18), which 
could predict lung functional decline and acute exacerbations 
and assess mortality risk.59
Fibrinogen seems to be the more stable and reproducible 
biomarker in COPD clinical studies, and in combination 
with leukocytosis and high CRP during the stable phase, 
allows the identification of patients who are predisposed to 
frequent exacerbations.60,61
CRP alone was studied in two prospective studies per-
formed on outpatients62 and inpatients59 to predict early 
relapse after an AECOPD. Following an exacerbation, 
higher serum levels of CRP at day 1462 and at discharge 
of hospitalization60 following the event were respectively 
predictive of a recurrent exacerbation event within 50 days 
of the index exacerbation,63 and in an early period following 
discharge (30 days).60 Interestingly, in the latter study,60 
high levels of CRP at discharge were not related to any of 
the clinical, therapeutic or severity variables included, sug-
gesting that a residual bacterial infection or a superinfec-
tion during treatment could underlie enhanced CRP levels 
after treatment, similarly to what happens in non-resolving 
exacerbations.63
About treatment failure, a Spanish prospective study 
on 378 AECOPD patients treated with both antibiotics and 
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steroids and aimed to determine inhospital predictors of 
treatment failure in a period #7 days found that +1 mg/dL of 
CRP at admission (odds ratio [OR] 1.07; 95% CI 1.01–1.13, 
P=0.014) increases the risk of failure.64
In addition, the level of serum magnesium56 and levels 
of serum D-dimer65 were studied and found to be associated 
with treatment failure and relapse.
Notwithstanding the scientific interest and promising 
results in clinical trial in distinguishing patients with early 
relapse or with frequent exacerbations, no biomarker is cur-
rently ready for use in the clinical management of AECOPD 
because of suboptimal performance.66
Microbiology
Recently, the expression “lung microbiome” has been used 
to describe the entire community of microorganisms that 
inhabit the lower respiratory tract and is investigated through 
modern molecular techniques which identify bacteria on 
the basis of ribosomal RNA sequences. These techniques 
have demonstrated that the bronchial tree is not a sterile 
environment, even in healthy people and that the respiratory 
microbiome changes in chronic lung diseases.67 The presence 
of these bacteria in the airways may increase chronic inflam-
mation that drives COPD pathogenesis and/or progression.68 
Even in patients with stable COPD, bacterial pathogens are 
detected in the lower respiratory tract of 25%–50% of cases 
when examined by the analysis of sputum, bronchoalveolar 
lavage, bronchial brushings or bronchial biopsies; this bacte-
rial chronic “colonization/infection” is associated with host 
inflammatory and immune responses. The increased risk of 
“colonization/infection” and airway inflammation has been 
associated with lower FEV
1
% and active smoking.69,70
In COPD, the lung microbiome changes during exacerba-
tions, irrespective of prescribed treatment regimens (antibi-
otics only, oral corticosteroids only or both).68 Interestingly, 
a recent study in severe COPD patients with Pseudomonas 
aeruginosa (PA) colonization revealed that lung microbiome 
composition changes during exacerbations and becomes 
similar to non-PA-colonized patients, where no predominant 
PA is usually found.71 These findings suggest that antibiotic 
therapy of exacerbations in COPD patients colonized by PA 
should not necessarily be directed exclusively at covering 
this microorganism.
In AECOPD patients, a key point related to an improve-
ment in clinical outcomes is the success of therapy.72 Data on 
sputum culture suggest that bacterial infections may often be 
the cause of AECOPD. A clear relationship has been proven 
between sputum purulence and the presence of bacteria.73
However, some patients treated with antibiotics show 
incomplete resolution, persistence or worsening of AECOPD 
symptoms/signs, defining an inhospital treatment failure.74 
Failure may be related to inadequate antibiotic efficacy, which 
through incomplete resolution of the initial exacerbation 
and persistent bacterial infection is likely to influence the 
risk of future relapse.75 In AECOPD inpatients, reported 
treatment failure rates vary between 10% and 39% of patients 
treated with both antibiotics and systemic steroids.76,77
Different trials have been conducted to demonstrate 
that antibiotic choice impacts on long-term outcomes in 
AECOPD, specifically in reducing clinical relapses, the need 
for additional antibiotics and prolonging the time to following 
exacerbation.78–81 However, not all studies demonstrated dif-
ferences in long-term outcomes between different antibiotic 
regimens (beta-lactams, quinolones, etc.). The mechanisms 
by which antibiotics improve long-term outcomes of COPD 
are not completely clear, but it is likely that the complete 
eradication of the bacteria involved in the exacerbation plays 
a major role.82
Patient-reported outcomes
Steer et al49 found that dyspnea intensity, measured by the 
Medical Research Council Dyspnea scale (MRCD) correlated 
with a progressive risk of readmission. Moreover, a new 
version of MRCD, defined as extended MRCD (eMRCD), 
evaluating patient ability in washing and dressing, has a 
better predictive ability in identifying patients requiring 
readmittance.
In addition, the ESFERA study showed that a simple 
tool such as the COPD Severity Scale (COPDSS),83 which 
evaluate the level of dyspnea at the moment of the evaluation, 
and in the previous 14 days, the need of rescue medications 
and the number and severity of hospitalization in the past 
5 years, could be used as the measurement of disease severity 
and therefore as a predictor of outcomes.84,85
Conclusion and recommendations
AECOPD patients, especially those requiring hospitalization, 
have a worse prognosis in terms of loss of lung function, 
quality of life and mortality. Increased exacerbation risk is 
related to the severity of COPD, comorbidities and, poten-
tially, the presence of a chronic airways infection (ie, PA) 
other than by different underlying biologic characteristics 
as listed in Table 1.
Strategies to identify different factors related to clinical 
characteristics of COPD patients and the identification of 
risk factors of failure and relapse may allow a more precise 
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approach with specific strategies or interventions targeting 
the individual needs of patients, with the aim of reducing the 
readmission rate in COPD patients.
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